Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
7 evidence topics · 7 sources
Phase 3 dose: 45 mg once daily selected by the independent data monitoring committee
Doses compared in the phase 2 portion of AMPLITUDE: 15 mg and 45 mg once daily
“The safety and efficacy of inaxaplin at 15 mg once daily and 45 mg once daily (which is in the lower range of doses explored in these phase 1 studies) is currently being evaluated in a randomized, double-blind, placebo-controlled, phase 2/3 adaptive trial in adults with AMKD (ClinicalTrials.gov number, NCT05312879).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2a regimen: 15 mg once daily for 2 weeks, then 45 mg once daily for 11 weeks
Rationale for the phase 2a doses
Maximum daily dose, total dose, and treatment duration in the EU trial record
| Field | Quoted record |
|---|---|
| Maximum daily dose | “45 mg milligram(s)” |
| Maximum total dose | “4860 mg milligram(s)” |
| Maximum duration of treatment | “108 week(s)” |